Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование PHST001 в современных солидных опухолях

30 сентября 2026 г. обновлено: Pheast Therapeutics

Открытое исследование, исследование фазы 1A/1B, эскалация дозы и расширения дозы, исследующее безопасность, фармакокинетику, фармакодинамику и противоопухолевую активность PHST001 у взрослых пациентов с современными рецидивирующими и/или рефрактерными твердыми опухолями

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.

The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.

Обзор исследования

Тип исследования

Интервенционный

Регистрация (Оцененный)

426

Фаза

  • Фаза 1

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Raphaël Rousseau, Chief Medical Officer, PhD, MD
  • Номер телефона: 650-260-8443
  • Электронная почта: medical@pheast.com

Места учебы

    • California
      • Beverly Hills, California, Соединенные Штаты, 90212
        • Рекрутинг
        • Precision NextGen Oncology & Research Center
        • Контакт:
        • Главный следователь:
          • Kamlesh Kumar Sankhala, MD
      • Los Angeles, California, Соединенные Штаты, 90033
      • Palo Alto, California, Соединенные Штаты, 94304
        • Рекрутинг
        • Stanford University School of Medicine
        • Контакт:
          • Kayla McDaniel
          • Номер телефона: 650-498-7293
          • Электронная почта: mcda59@stanford.edu
        • Главный следователь:
          • Oliver Dorigo, MD, PhD
    • Colorado
      • Denver, Colorado, Соединенные Штаты, 80218
        • Рекрутинг
        • Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
        • Контакт:
    • Connecticut
      • New Haven, Connecticut, Соединенные Штаты, 06520
        • Рекрутинг
        • Yale Cancer Center
        • Главный следователь:
          • Michael Cecchini, MD
        • Контакт:
          • Priscilla Stéve
          • Номер телефона: 203-464-5564
          • Электронная почта: Priscilla.steve@yale.edu
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60637
        • Рекрутинг
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02215
        • Рекрутинг
        • Dana Farber Cancer Institute
        • Главный следователь:
          • Michael Dennis, MD
        • Контакт:
    • Michigan
      • Ann Arbor, Michigan, Соединенные Штаты, 48109
        • Рекрутинг
        • University of Michigan Rogel Cancer Center
        • Главный следователь:
          • Ulka Vaishampayan, MD
        • Контакт:
          • University of Michigan Health Cancer AnswerLine
          • Номер телефона: 1-800-865-1125
          • Электронная почта: canceranswerline@med.umich.edu
      • Grand Rapids, Michigan, Соединенные Штаты, 49546
        • Рекрутинг
        • START Center for Cancer Research - Midwest
        • Главный следователь:
          • Sreenivasa Chandana, MD, PhD
        • Контакт:
    • New York
      • Lake Success, New York, Соединенные Штаты, 11042
        • Рекрутинг
        • START Center for Cancer Research - Long Island New York
        • Главный следователь:
          • Geraldine O'Sullivan Coyne, MD
        • Контакт:
      • New York, New York, Соединенные Штаты, 10029
        • Рекрутинг
        • Mount Sinai
        • Главный следователь:
          • Thomas Marron, MD, PhD
        • Контакт:
          • Jordan Cuevas
          • Номер телефона: 212-824-7945
          • Электронная почта: jordan.cuevas@mssm.edu
    • North Carolina
      • Durham, North Carolina, Соединенные Штаты, 27710
        • Рекрутинг
        • Duke Cancer Institute
        • Контакт:
        • Главный следователь:
          • Niharika Mettu, MD, PhD
    • Tennessee
      • Nashville, Tennessee, Соединенные Штаты, 37203
        • Рекрутинг
        • Vanderbilt-Ingram Cancer Center
        • Контакт:
          • Clinical Trials Office (CTO)
          • Номер телефона: 1-800-811-8480
          • Электронная почта: cip@vumc.org
        • Главный следователь:
          • Elizabeth Davis, MD, PhD
      • Nashville, Tennessee, Соединенные Штаты, 37203
        • Рекрутинг
        • Sarah Cannon Research Institute (SCRI) Oncology Partners
        • Главный следователь:
          • Deepak Bhamidipati, MD
        • Контакт:
          • SCRI Oncology Partners - Nashville
          • Номер телефона: 1-877-MY-1-SCRI (691-7274)
          • Электронная почта: ASKSARAH@scresearch.net
    • Texas
      • Fort Worth, Texas, Соединенные Штаты, 76104
        • Рекрутинг
        • START Center for Cancer Research - Texas
        • Контакт:
        • Главный следователь:
          • Henry Xiong, MD, PhD
      • Houston, Texas, Соединенные Штаты, 77030
        • Рекрутинг
        • MD Anderson Cancer Center
        • Контакт:
          • MD Anderson Cancer Center
          • Номер телефона: 713-563-1930
          • Электронная почта: ICTNPCS@mdanderson.org
        • Главный следователь:
          • Stéphane Champiat, MD, PhD
      • Irving, Texas, Соединенные Штаты, 75039
        • Рекрутинг
        • NEXT Oncology - Dallas
        • Главный следователь:
          • Michael Song, MD, PhD, PharmD
        • Контакт:
      • San Antonio, Texas, Соединенные Штаты, 78229
        • Рекрутинг
        • University of Texas (UT) Health
        • Главный следователь:
          • Daruka Mahadevan, MD, PhD
        • Контакт:
      • San Antonio, Texas, Соединенные Штаты, 78229
        • Рекрутинг
        • START Center for Cancer Research - San Antonio
        • Главный следователь:
          • Kyriakos Papadopoulos, MD
        • Контакт:
    • Virginia
      • Fairfax, Virginia, Соединенные Штаты, 22031

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Key Inclusion Criteria:

  • Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
  • Adequate organ function per laboratory testing
  • Pregnancy prevention requirements
  • Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
  • Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale

Key Exclusion Criteria:

  • Diagnosis of immunodeficiency
  • History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
  • Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
  • Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
  • Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
  • Received previous treatment with another agent targeting CD24.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Последовательное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: PHST001 Monotherapy

Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Экспериментальный: PHST001 + Paclitaxel

Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Paclitaxel used as per standard of care.

Другие имена:
  • Таксол
Экспериментальный: PHST001 + Topotecan

Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Topotecan used as per standard of care.

Другие имена:
  • Гикамтин
Экспериментальный: PHST001 + Doxorubicin

Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Doxorubicin used as per standard of care.

Другие имена:
  • Адриамицин
Экспериментальный: PHST001 + FOLFIRI

Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

FOLFIRI used as per standard of care.

Другие имена:
  • folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan combination
Экспериментальный: PHST001 + FOLFOX

Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

FOLFOX used as per standard of care.

Другие имена:
  • folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin combination
Экспериментальный: PHST001 + Gemcitabine

Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Gemcitabine used as per standard of care.

Другие имена:
  • Гемзар
Экспериментальный: PHST001 + Mirvetuximab Soravtansine

Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Mirvetuximab soravtansine used as per standard of care.

Другие имена:
  • MIRV, Elahere
Экспериментальный: PHST001 + Trastuzumab Deruxtecan

Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Trastuzumab deruxtecan used as per standard of care.

Другие имена:
  • T-DXd, Энэрту
Активный компаратор: Mirvetuximab Soravtansine Monotherapy

Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy.

Mirvetuximab soravtansine used as per standard of care.

Другие имена:
  • MIRV, Elahere

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From first dose of PHST001 through 21 days after the first dose of PHST001

Based on toxicities observed

From first dose of PHST001 through 21 days after the first dose of PHST001
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From signed consent up to 90 days after the last dose of PHST001

Based on toxicities observed

From signed consent up to 90 days after the last dose of PHST001
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
Временное ограничение: From screening and during treatment up to 2 years

Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
Временное ограничение: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

From screening and during treatment up to 2 years

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
Временное ограничение: From screening and during treatment up to 2 years

Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

From screening and during treatment up to 2 years
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Временное ограничение: From screening and during treatment up to 2 years

Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression.

From screening and during treatment up to 2 years
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Временное ограничение: From screening and during treatment up to 2 years

Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment.

From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
Временное ограничение: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

From screening and during treatment up to 2 years
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
Временное ограничение: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to the date of death.

From screening and during treatment up to 2 years
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
Временное ограничение: From treatment until 90 days after last dose of PHST001

Defined as the maximum blood concentration of a dose of PHST001

From treatment until 90 days after last dose of PHST001
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From treatment until 90 days after last dose of PHST001

Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration.

From treatment until 90 days after last dose of PHST001
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From treatment until 90 days after last dose of PHST001

Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration).

From treatment until 90 days after last dose of PHST001
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From treatment until 90 days after last dose of PHST001

Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile.

From treatment until 90 days after last dose of PHST001
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From treatment until 90 days after last dose of PHST001

Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered.

From treatment until 90 days after last dose of PHST001
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From treatment until 90 days after last dose of PHST001

Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream.

From treatment until 90 days after last dose of PHST001
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Временное ограничение: From treatment until 90 days after last dose of PHST001

Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination.

From treatment until 90 days after last dose of PHST001

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

31 марта 2025 г.

Первичное завершение (Оцененный)

1 апреля 2029 г.

Завершение исследования (Оцененный)

1 апреля 2031 г.

Даты регистрации исследования

Первый отправленный

10 февраля 2025 г.

Впервые представлено, что соответствует критериям контроля качества

18 февраля 2025 г.

Первый опубликованный (Действительный)

21 февраля 2025 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

5 октября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

30 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • PHST001-101

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться